Jiangsu Huili Biological Technology, located in the Taizhou Medical High-tech Zone in Taizhou, East China's Jiangsu province, has persisted in adopting synthetic biology technology instead of traditional chemical methods for production.
That has led to palpable advantages in its efficient, low carbon and sustainable development.
Synthetic biology has the capacity to continuously produce specific substances through targeted design, modification and synthesis. It is mainly used in fields of medical drugs, chemical products and carbon neutrality.
"How to move from laboratory to large-scale production is a major point in synthetic biology, but it is also the advantage of Huili," said Guo Hongming, chairman of the company.
In 2017, the company developed its star product, pyrazine carboxylic acid. That made it become the world's first company to use synthetic biotechnology to produce pyrazine carboxylic acid and helped solve the problem of heavy pollution in the production process.
In addition, the construction of an independent pilot platform is widely seen in the industry as being indispensable for large-scale production. As a result, the company invested 15 million yuan ($2.11 million) to build a pilot platform, which can meet diverse needs of different substances for various stages of pilot testing.
A technician gets to work at the 6,000-square-meter production factory run by Jiangsu Huili Biological Technology. [Photo/WeChat account: weigg6666]